Certain relatively small cells present in the periphery blood of mammals can be activated to form pluripotent stem cell populations. These small cells are generally less than five micrometers in diameter and are CD45-positive, and are referred to herein as CD45.sup.+ cells or dormant tiny cells. Accordingly, provided are cell populations and compositions with enriched dormant tiny cells from blood samples and methods and compositions for activating these dormant tiny cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

The disclosure features methods of correcting a mutation in the human beta-globin (HBB) gene in a cell or population of cells. The disclosure also features methods of increasing repair of a DNA double stranded break (DSB) in an HBB gene by the homology-directed repair (HDR) pathway. The disclosure also features compositions for use in the methods.

The disclosure features methods of correcting a mutation in the human beta-globin (HBB) gene in a cell or population of cells. The disclosure also features methods of increasing repair of a DNA double stranded break (DSB) in an HBB gene by the homology-directed repair (HDR) pathway. The disclosure also features compositions for use in the methods.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of osteoarthritis in canines and felines. For example, the MSCs or pharmaceutical composition can be used in the treatment of lameness and/or joint pain in canines and felines diagnosed with or suffering from osteoarthritis. A pharmaceutical composition comprising MSCs can be isolated from peripheral blood.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of osteoarthritis in canines and felines. For example, the MSCs or pharmaceutical composition can be used in the treatment of lameness and/or joint pain in canines and felines diagnosed with or suffering from osteoarthritis. A pharmaceutical composition comprising MSCs can be isolated from peripheral blood.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.